Talk:Antiplatelet drug

From Wikipedia, the free encyclopedia
Jump to: navigation, search
WikiProject Pharmacology (Rated Start-class, Top-importance)
WikiProject icon This article is within the scope of WikiProject Pharmacology, a collaborative effort to improve the coverage of Pharmacology on Wikipedia. If you would like to participate, please visit the project page, where you can join the discussion and see a list of open tasks.
Start-Class article Start  This article has been rated as Start-Class on the project's quality scale.
 Top  This article has been rated as Top-importance on the project's importance scale.
 
WikiProject Medicine (Rated Start-class, Mid-importance)
WikiProject icon This article is within the scope of WikiProject Medicine, which recommends that this article follow the Manual of Style for medicine-related articles and use high-quality medical sources. Please visit the project page for details or ask questions at Wikipedia talk:WikiProject Medicine.
Start-Class article Start  This article has been rated as Start-Class on the project's quality scale.
 Mid  This article has been rated as Mid-importance on the project's importance scale.
 

Price?[edit]

I deleted the following sentence:

Further, "...the cost to prevent one major GI bleeding episode from aspirin in 1 year by substituting clopidogrel therapy would be $1,216,180..."

Putting a calulation on GI Bleeding seems to indicate that there is a savings by using Plavix. This would have to include a detailed analysis of the cost of the drug and the cost of side effects from the drug vs. the cost of asprin and the side effects from asprin.

The sentence seemed to indicate that there were no peripheral cost associated with the use of an antiplatelets. As there are side-effects with antiplatelets there are also additional cost. Qualifying these cost would be too distractive from the topic. Jeffjacks7 03:08, 22 March 2007 (UTC)

Resistance[edit]

doi:10.1136/heartjnl-2013-304461 something like 30% of all people on antiplatelets are resistant, and the outcomes are better once antiplatelets are tailored to their response.

Now we need a cost-effectiveness assessment, and platelet function testing is going to enter widespread use. JFW | T@lk 17:06, 11 December 2013 (UTC)